New Drug Futures Report Estimates That Anti-Infectives Grossed Sales of US$28.5 Billion in 2005.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c37819) has announced the addition of New Drug Futures: Anti-Infective Chapter to their offering. This chapter of New Drug Futures evaluates, compares and contrasts the prospects for the compounds that will revolutionise Verb 1. revolutionise - fill with revolutionary ideas revolutionize, inspire indoctrinate - teach doctrines to; teach uncritically; "The Moonies indoctrinate their disciples" 2. the pharmaceutical industry over the next 5 years and beyond in the anti-infective sector. The report includes unique sales forecasts Sales forecast A key input to a firm's financial planning process. External sales forecasts are based on historical experience, statistical analysis, and consideration of various macroeconomic factors. by major product. The anti-infectives market is the fifth largest therapeutic category. The report estimates that anti-infectives grossed sales of US$28.5 billion in 2005, with a further US$16 billion being derived from hospital-based use and OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). . The majority of prescription-based sales were derived from the US (around 50%) compared to 22% in Europe and Japan. However, growth in Europe at over 5% exceeded that of the US and Japan compared with around 3%. ANTIBIOTIC antibiotic, any of a variety of substances, usually obtained from microorganisms, that inhibit the growth of or destroy certain other microorganisms. Types of Antibiotics SALES It is estimated the antibiotic market is currently worth nearly US$31 billion, equivalent to around 5% of total global pharmaceutical sales. The market for anti-MRSA antibiotics is expected to reach US$2 billion by 2006, driven by the sales of Pfizer's Zyvox which is available as IV or oral formulation and generated sales of US$618 million in 2005. In contrast, the market for non-MRSA hospital antibiotics is currently valued at around $6 billion. ANTIVIRAL antiviral /an·ti·vi·ral/ (-vi´ral) destroying viruses or suppressing their replication, or an agent that so acts. an·ti·vi·ral adj. SALES It is forecasted that nearly US$9.8 billion was spent globally on the treatment of antiviral medicines in 2005. The largest segment of this market is derived from the treatment of HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. , with reported sales of around US$7 billion. The US market accounts for around 60%, equating e·quate v. e·quat·ed, e·quat·ing, e·quates v.tr. 1. To make equal or equivalent. 2. To reduce to a standard or an average; equalize. 3. to over US$5 billion, whilst in Europe, France has the largest market value with revenues of around US$600 million. HIV-reverse transcription inhibitors were amongst the top 20 leading therapeutic drug classes (based on 2005 US sales) generating global sales of US$5 billion with products such GSK's Combivir. The second largest segment of the antiviral market is derived from the treatment of hepatitis B/C B/C Because B/C Broadcast B/C Boundary Conditions B/C Biological & Chemical which reported sales of around US$3 billion in 2005, generated from combination therapies (pegylated interferon interferon (ĭn'tərfēr`ŏn), any of a group of proteins produced by cells in the body in response to an attack by a virus. A cell infected by a virus releases minute amounts of interferons, which attach themselves to neighboring cells, and ribavarin) for the treatment of HCV HCV abbr. hepatitis C virus HCV 1 Hepatitis C virus, see there 2. Human coronavirus. See Coronavirus. . This market is dominated by two players: Roche which commands over 60% of the US and global pegylated interferon market through the sale of Pegasys/Copegus (US$1.9 billion in 2005) and Schering-Plough through the sale of PegIntron/ Rebetrol (US$1.1 billion in 2005). Answering key business questions: - Which antifungal agent is expected to achieve peak sales of US$1.2 billion? - Who will win the race to exploit the novel anti-retroviral CCR5 inhibitors? - If approved, Merck's MK-0518 will be first in class of novel integrase inhibitors to reach the market. What might its market value be and when will it be launched? Companies and Drugs Mentioned: - Anidulafungin (Pfizer) - Aptivus (Boehringer Ingelheim) - Aplaviroc (GlaxoSmithKline) - Ceftobiprole (Johnson & Johnson) - Garenoxicin (Schering-Plough) - GW695634 (GlaxoSmithKline) - Maraviroc (Pfizer) - MK-0518 (Merck & Co) - Retapamulin (GlaxoSmithKline) - Telbivudine (Novartis) - TMC-114 (Johnson & Johnson/Tibotec Pharma) - Tygacil (Wyeth) - Vicriviroc (Schering-Plough) - VX-950 (Vertex Pharmaceuticals) - Zeven (Pfizer) For more information visit http://www.researchandmarkets.com/reports/c37819 |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion